NCT05379569View on ClinicalTrials.gov

Comparative Study of BFC and BuCy Conditioning Regimen for Allo-PBSCT in Acute B-cell ALL

PHASE4RecruitingINTERVENTIONAL
Enrollment

142

Participants

Timeline

Start Date

May 15, 2022

Primary Completion Date

November 30, 2023

Study Completion Date

December 30, 2025

Conditions
Acute B Lymphoblastic LeukemiaAllogeneic Hematopoietic Stem Cell Transplantation
Interventions
DRUG

Fludarabine

The combination of fludarabine and cyclophosphamide has synergistic effect, which can better kill B lymphocyte, and can enhance the killing effect of pretreatment regimen on B lymphocyte tumor.

Trial Locations (1)

Unknown

RECRUITING

Shanghai General Hospital, Shanghai

All Listed Sponsors
lead

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

OTHER